Brigatinib for ALK-positive advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor – guidance (TA670)

NICE recommend brigatinib as an option for ALK+ve advanced non-small-cell lung cancer that has not been previously treated with an ALK inhibitor in adults. It is recommended only if the company provides brigatinib according to the commercial arrangement.

National Institute for Health and Care Excellence